Efficacy of intravitreal methotrexate for intraocular lymphoma

Efficacy of intravitreal methotrexate for intraocular lymphoma - Intravitreal methotrexate for intraocular lymphoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004451

Enrollment

Registered

2010-11-01

Start date

2010-12-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intraocular lymphoma

Interventions

Intravitreal methotrexate injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patient of intraocular lymphoma 2)Written informed consent 3)Patient who was judged by doctor to be able to receive the protocol therapy

Exclusion criteria

Exclusion criteria: 1)History of serious adverse reactions by methotrexate 2)Infectious disease of eye 3)Patient who was judged by doctor not to be able to receive drug

Design outcomes

Primary

Measure	Time frame
visual acuity, funduscopy, slit-lamp biomicroscopy, complication	—

Countries

Japan

Contacts

Public ContactMariko Egawa

Institute of Health Biosiences, The University of Tokushima Graduate School Ophthalmology

egawa.m@tokushima-u.ac.jp088-633-7163

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026